Sunil Nagpal

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Vitamin D receptor as a drug discovery target
    Karen V Pinette
    Gene Regulation, Bone and Inflammation Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN-46285, USA
    Mini Rev Med Chem 3:193-204. 2003
  2. ncbi Noncalcemic actions of vitamin D receptor ligands
    Sunil Nagpal
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Endocr Rev 26:662-87. 2005
  3. ncbi Vitamin D receptor modulators for inflammation and cancer
    Ying K Yee
    Discovery Chemistry, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Mini Rev Med Chem 5:761-78. 2005
  4. ncbi Vitamin D analogs: mechanism of action and therapeutic applications
    S Nagpal
    Gene Regulation, Bone and Inflammation Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN 46285, USA
    Curr Med Chem 8:1661-79. 2001
  5. ncbi Transcriptional profiling of keratinocytes reveals a vitamin D-regulated epidermal differentiation network
    Jianfen Lu
    Bone and Inflammation Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Invest Dermatol 124:778-85. 2005
  6. ncbi Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators
    Yanfei Ma
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Clin Invest 116:892-904. 2006
  7. ncbi Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation
    David J Bettoun
    Gene Regulation, Bone and Inflammation Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Mol Endocrinol 17:2320-8. 2003
  8. ncbi Ligand modulates VDR-Ser/Thr protein phosphatase interaction and p70S6 kinase phosphorylation in a cell-context-dependent manner
    David J Bettoun
    Inflammation, Immunomodulation, Gene Regulation and Bone Research, Indianapolis, IN-46285, USA
    J Steroid Biochem Mol Biol 89:195-8. 2004
  9. ncbi Coactivation of the human vitamin D receptor by the peroxisome proliferator-activated receptor gamma coactivator-1 alpha
    Rajesh S Savkur
    Eli Lilly and Company, DC0434, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Mol Pharmacol 68:511-7. 2005
  10. ncbi A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand
    David J Bettoun
    Gene Regulation, Bone, and Inflammation Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 277:24847-50. 2002

Collaborators

  • Thomas P Burris
  • Shigeaki Kato
  • David J Bettoun
  • Shuguang Huang
  • Keith A Houck
  • Boris J Cheskis
  • Subba R Chintalacharuvu
  • Jianfen Lu
  • Ying K Yee
  • Yanfei Ma
  • Leonard P Freedman
  • Rajesh S Savkur
  • Songqing Na
  • William W Chin
  • Qing Q Zeng
  • Srinivasan Chandrasekhar
  • Edward J Kilbourne
  • Kelli S Bramlett
  • Keith R Stayrook
  • Karen V Pinette
  • Clint Schmidt
  • Jingyong Zhao
  • William J Moore
  • GLENNA C BURMER
  • George E Sandusky
  • James G Greger
  • Yoko Yamamoto
  • Jared H Linebarger
  • Ai Memezawa
  • Xiao-peng Yu
  • Berket Khalifa
  • Kazuyoshi Yamaoka
  • Stephen J Iturria
  • Lawrence M Gelbert
  • Peining Chen
  • Keith M Goldstein
  • Bernard Y Amegadzie

Detail Information

Publications17

  1. ncbi Vitamin D receptor as a drug discovery target
    Karen V Pinette
    Gene Regulation, Bone and Inflammation Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN-46285, USA
    Mini Rev Med Chem 3:193-204. 2003
    ..This review presents recent advances in VDR biology, novel VDR ligands and therapeutic applications of VDR ligands...
  2. ncbi Noncalcemic actions of vitamin D receptor ligands
    Sunil Nagpal
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Endocr Rev 26:662-87. 2005
    ..This review deals with the molecular aspects of noncalcemic actions of vitamin D analogs that account for the efficacy of VDR ligands in the above-mentioned indications...
  3. ncbi Vitamin D receptor modulators for inflammation and cancer
    Ying K Yee
    Discovery Chemistry, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Mini Rev Med Chem 5:761-78. 2005
    ..This review explores the recent advances in VDR biology, non-secosteroidal VDR ligands and the current and potential clinical applications of VDR ligands in inflammation and cancer...
  4. ncbi Vitamin D analogs: mechanism of action and therapeutic applications
    S Nagpal
    Gene Regulation, Bone and Inflammation Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN 46285, USA
    Curr Med Chem 8:1661-79. 2001
    ..The discovery of novel vitamin D3 analogs along with an increased understanding of the biological functions and mechanisms of action of VDR are likely to result in improved treatments for responsive indications...
  5. ncbi Transcriptional profiling of keratinocytes reveals a vitamin D-regulated epidermal differentiation network
    Jianfen Lu
    Bone and Inflammation Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Invest Dermatol 124:778-85. 2005
    ....
  6. ncbi Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators
    Yanfei Ma
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Clin Invest 116:892-904. 2006
    ....
  7. ncbi Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation
    David J Bettoun
    Gene Regulation, Bone and Inflammation Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Mol Endocrinol 17:2320-8. 2003
    ....
  8. ncbi Ligand modulates VDR-Ser/Thr protein phosphatase interaction and p70S6 kinase phosphorylation in a cell-context-dependent manner
    David J Bettoun
    Inflammation, Immunomodulation, Gene Regulation and Bone Research, Indianapolis, IN-46285, USA
    J Steroid Biochem Mol Biol 89:195-8. 2004
    ....
  9. ncbi Coactivation of the human vitamin D receptor by the peroxisome proliferator-activated receptor gamma coactivator-1 alpha
    Rajesh S Savkur
    Eli Lilly and Company, DC0434, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Mol Pharmacol 68:511-7. 2005
    ..The coactivation potential of PGC-1alpha requires an intact AF-2 domain of VDR and the LXXLL motif in PGC-1alpha. Taken together, these results indicate that PGC-1alpha serves as a coactivator for VDR...
  10. ncbi A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand
    David J Bettoun
    Gene Regulation, Bone, and Inflammation Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 277:24847-50. 2002
    ..Since p70(S6k) is essential for G(1)-S transition, our results provide a molecular basis of 1alpha,25-dihydroxyvitamin D(3)-induced G(1) block in colon cancer cells...
  11. ncbi Retinoids: inducers of tumor/growth suppressors
    Sunil Nagpal
    Bone and Inflammation Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Invest Dermatol 123:xx-xxi. 2004
  12. ncbi Liver X receptor is a therapeutic target in collagen-induced arthritis
    Subba R Chintalacharuvu
    Eli Lilly and Company, Indianapolis, IN, USA
    Arthritis Rheum 56:1365-7. 2007
  13. ncbi A Nonsecosteroidal Vitamin D Receptor Modulator Ameliorates Experimental Autoimmune Encephalomyelitis without Causing Hypercalcemia
    Songqing Na
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Autoimmune Dis 2011:132958. 2011
    ..Finally, we demonstrate that the oral administration of compound A inhibited the induction and progress of experimental autoimmune encephalomyelitis in mice without causing hypercalcemia...
  14. ncbi Vitamin D receptor ligands for osteoporosis
    Boris J Cheskis
    Wyeth Research, VVomen's Health and Musculoskeletal Biology, 500 Arcola Road, Collegeville, PA 19426, USA
    Curr Opin Investig Drugs 7:906-11. 2006
    ..The future directions of vitamin D research for the discovery of novel VDR agonists for osteoporosis are also discussed...
  15. ncbi An orphan meets family members in skin
    Sunil Nagpal
    J Invest Dermatol 120:viii-x. 2003
  16. ncbi Signaling by estrogens
    Boris J Cheskis
    Women s Health and Musculoskeletal Biology, Wyeth Research, Collegeville, Pennsylvania 19426, USA
    J Cell Physiol 213:610-7. 2007
    ....
  17. ncbi Selective androgen receptor modulators for frailty and osteoporosis
    Edward J Kilbourne
    Women s Health and Musculoskeletal Biology, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA
    Curr Opin Investig Drugs 8:821-9. 2007
    ..This article reviews the mechanism of androgen action, novel non-steroidal ligands under development and future directions of SARM research for the discovery of novel modulators for frailty and osteoporosis...